While there had been some doubt if Isis (ISIS 5.47%) and its partner Sanofi (SNY +2.01%) would have their inherited cholesterol disorder drug Kynamro approved, news today that it received FDA approval shot Isis shares up 10%, while competitor Aegerion (NASDAQ: AEGR) was down 2% on the news. In this video, Motley Fool health-care analyst David Williamson tells us some of the headwinds and tailwinds investors can expect for the drug, and how well he sees it competing with Aegerion's Juxtapid in the same space.
Isis Aces its Test
By Dave Williamson – Jan 30, 2013 at 4:32PM
NASDAQ: IONS
Ionis Pharmaceuticals
Market Cap
$11B
Today's Change
(-5.47%) $4.02
Current Price
$69.53
Price as of November 10, 2025 at 3:58 PM ET
Isis gets a big approval.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid